Skip to main content
. Author manuscript; available in PMC: 2020 Nov 15.
Published in final edited form as: Int J Cancer. 2020 May 25;147(10):2725–2734. doi: 10.1002/ijc.33043

FIGURE 1.

FIGURE 1

Adjusted cumulative incidence curves for CRC-specific mortality according to vitamin D status-using Institute of Medicine recommended 25-hydroxyvitamin D cut-points-in the combined EPIC and CPS-II cohort (n = 1281) among, A, patients without Gc2 (GC rs4588*CC) and B, patients with Gc2 (GC rs4588*CA or AA). Cumulative incidence curves were estimated using Fine and Gray’s competing-risks regression models adjusted for age at diagnosis (continuous), year of diagnosis (continuous), sex, tumor site (colon, rectum, missing/not specified), BMI (continuous), physical activity (Quartiles 1–4, missing), smoking status (never, former, current, missing), stage (I-IV, missing/not specified) and country. 25(OH)D concentrations <30, 30 to <50 and ≥50 nmol/L categorized as deficient, insufficient and sufficient, respectively, based on the Institute of Medicine guidelines